Telmisartan in the management of diabetic nephropathy: A contemporary view

Current Diabetes Reviews

Volumn 8, Issue 3, 2012, Pages 183-190

  Balakumar, Pitchai ^a   Bishnoi, Harish K ^a   Mahadevan, Nanjaian ^a  

^a Rajendra Institute of Technology and Sciences   (India)

Author keywords

AT 1receptor blockade; Diabetic nephropathy; PPAR partial agonism; Renoprotection; Telmisartan

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SUPEROXIDE DISMUTASE; TELMISARTAN;

AGE; ANTIDIABETIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DOWN REGULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENZYME INACTIVATION; FLUID RETENTION; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MICROALBUMINURIA; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; SIDE EFFECT; WEIGHT GAIN;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; TREATMENT OUTCOME;

EID: 84861159160     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339912800563972     Document Type: Review

References (82)

1. Wild S, Roqlic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimated for the year 2000 and projection of 2030. Diabetes Care 2004; 27: 1047-53.
2. Kozek E, Górska A, Fross K, Marcinowska A, Citkowska A, Sieradzki J. Chronic complications and risk factors in patients with type 1 diabetes mellitus-retrospective analysis. Przegl Lek 2003; 60: 773-7.
3. Balakumar P, Arora MK, Ganti SS, Reddy J, Singh M. Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions. Pharmacol Res 2009; 60: 24-32.
4. Soldatos G, Cooper ME. Diabetic Nephropathy: important pathophysiologic mechanisms. Diabetic Res Clin Pract 2008; 82: S75-9.
5. Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 2000; 26: 8-14.
6. Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 2007; 106: 26-31.
7. Kanwar YS, Wada J, Sun L, et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 2008; 233: 4-11.
8. Balakumar P, Chakkarwar VA, Kumar V, Jain A, Reddy J, Singh M. Experimental models for nephropathy. J Renin Angiotensin Aldosterone Syst 2008; 9: 189-95.
9. Balakumar P, Jagadeesh G. Cardiovascular and renal pathologic implications of prorenin, renin, and the (pro)renin receptor: promising young players from the old renin-angiotensin-aldosterone system. J Cardiovasc Pharmacol 2010; 56: 570-9.
10. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patient with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-20.
11. Balakumar P, Arora MK, Reddy J, Anand-Srivastava MB. Pathogenesis of diabetic nephropathy: involvement of multifaceted signalling mechanism. J Cardiovasc Pharmacol 2009; 54: 129-38.
12. Balakumar P, Reddy J, Singh M. Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy? Mol Cell Biochem 2009; 330: 187-92.
13. Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis 2011; 218: 13-8.
14. Leehey DJ, Singh AK, Alavi N, Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000; 77: S93-8.
15. Gnudi L, Goldsmith D. Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes. F1000 Med Rep 2010; 2. pii: 18.
16. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetic Care 2005; 28: 164-76.
17. Hahr AJ, Molitch ME. Diabetes, cardiovascular risk and nephropathy. Cardiol Clin 2010; 28: 467-75.
18. Sharma AM, Weir MR. The role of angiotensin receptor blockers in diabetic nephropathy. Postgrad Med 2011; 123: 109-21.
19. Doggrell SA. Telmisartan - killing two birds with one stone. Expert Opin Pharmacother 2004; 5: 2397-400.
20. Lakshmanan AP, Watanabe K, Thandavarayan RA, et al. Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-γ agonist action. Free Radic Res 2011; 45: 575-84.
21. Weinbergová O, Metelka R, Vymetal J, Konecný K, Kosatíková Z. Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2004; 148: 69-73.
22. Tuck ML. Angiotensin-receptor blocking agent and peroxisome proliferator-activated receptor-gamma system. Curr Hypertens Rep 2005; 7: 240-3.
23. Younis F, Stern N, Limor R, Oron Y Zanqen S, Rosenthal T. Telmisartan ameliorates hyperglycemia and metabolic profile in non obese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activated receptor-gamma activation. Metabolism 2010; 59: 1200-9.
24. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
25. Burnier M. Telmisartan: a different angiotensin II receptor blocker protecting a different population? J Int Med Res 2009; 37: 1662-79.
26. Tian Q, Miyazaki R, Ichiki T, et al. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptorgamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta. Hypertension 2009; 53:798-804.
27. Wienen W, Richard S, Champeroux P, Audeval-Gerard C. Comparative antihypertensive and renoprotective effect of telmisartan and lisinopril after long term treatment in hypertensive diabetic rats. J Renin Angiotensin Aldosterone Syst 2001; 2:31-6.
28. Bakris G, Burgess E, Weir M, Davidai G, Koval S; AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008; 74: 364-9.
29. Khan AH, Imig JD. Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome. Am J Hypertens 2011; 24: 816-21.
30. Jugdutt BI. Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clin Interv Aging 2010; 5: 403-16.
31. Balakumar P, Rose M, Singh M. PPAR ligands: are they potential agent for cardiovascular disorders? Pharmacology 2007; 80: 1-10.
32. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M. PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res 2007; 56: 91-8.
33. Wienen W, Hauel N, Van Meel JC, Narr B, Ries U, Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993; 110: 245-52.
34. Timmermans PB. Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol 1999; 15: 26F-8F.
35. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press Suppl 2001; 1: 6-11.
36. Kumar AS, Ghosh S, Mehta GN. Efficient and improved synthesis of telmisartan. Beilstein J Org Chem 2010; 6:25.
37. Ohno K, Amano Y, Kakuta H, et al. Unique "delta lock" structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor. Biochem Biophys Res Commun 2011; 404: 434-7.
38. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000; 28: 149-67.
39. Deppe S, Böger RH, Weiss J, Benndorf RA. Telmisartan: a review of its pharmacodynamics and pharmacokinetics properties. Expert Opin Drug Metab Toxicol 2010; 6: 863-71.
40. Stangier J, Su CA, Brickl R, Franke H. Pharmacokinetics of singledose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: Comparison with healthy volunteers. J Clin Pharmacol 2000; 40: 1365-72.
41. Tatami S, Sarashina A, Yamamura N, Igarashi T, Tanigawara Y. Population pharmacokinetics of an angiotensin II receptor antagonist, telmisartan, in healthy volunteers and hypertensive patients. Drug Metab Pharmacokinet 2003; 18: 203-11.
42. Takai S, Kirimura K, Jin D, et al. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 2005; 28: 593-600.
43. Ebner T, Heinzel G, Prox A, Beschke K, Wachsmuth H. Disposition and chemical stability of telmisartan-1-O-acylglucuronide. Drug Metab Dispos 1999; 27: 1143-9.
44. Maillard MP, Perregaux C, Centeno C, et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 2002; 302: 1089-95.
45. Hernández-Hernández R, Sosa-Canache B, Velasco M, Armas-Hernández MJ, Armas-Padilla MC, Cammarata R. Angiotensin II receptor antagonists role in arterial hypertension. J Hum Hypertens 2002; 16: S93-9.
46. Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs 2006; 66: 51-83.
47. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-7.
48. Imayama I, Ichiki T, Inanaga K, et al. Telmisartan downregulates angiotensin II type 1 receptorthrough activation of peroxisome proliferator- activated receptor gamma. Cardiovasc Res 2006; 72: 184-90.
49. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005; 54: 3442-52.
50. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 2001; 60: 14-30.
51. Barnett A. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. J Am Soc Nephrol 2006; 17: S132-5.
52. Makita S, Abiko A, Naganuma Y, Moriai Y, Nakamura M. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. Metabolism 2008; 57: 1473-8.
53. Matsui T, Yamagishi S, Ueda S, et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 2007; 35: 482-9.
54. Coughlan MT, Mibus AL, Forbes JM. Oxidative stress and advanced glycation in diabetic nephropathy. Ann N Y Acad Sci 2008; 1126: 190-3.
55. Yoshida T, Yamagishi S, Nakamura K, et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 2006; 49: 3094-9.
56. Yamagishi S, Matsui T, Nakamura K, Takeuchi M, Inoue H. Telmisartan inhibits advanced glycation end products (AGEs)- elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptorgamma activation. Protein Pept Lett 2008; 15: 850-3.
57. Tsunenari I, Ohmura T, Seidler R, et al. Renoprotective effects of telmisartan in the 5/6 nephrectomised rats. J Renin Angiotensin Aldosterone Syst 2007; 8: 93-100.
58. Balakumar P, Chakkarwar VA, Singh M. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol Cell Biochem 2009; 320: 149-62.
59. Nakagawa T, Tanabe K, Croker BP, et al. Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol 2011; 7: 36-44.
60. Wenzel P, Schulz E, Oelze M, et al. AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats. Free Radic Biol Med 2008; 45: 619-26.
61. Fujita H, Sakamoto T, Komatsu K, et al. Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy. Hypertens Res 2011; 34: 1302-8.
62. Rysavá R, Tesar V, Merta M; for the Czech Group for the Study of Glomerulonephritis. Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease. Blood Press Monit 2005; 10: 207-13.
63. Remuzzi A, Remuzzi G. Potential protective effects of telmisartan on renal function deterioration. J Renin Angiotensin Aldosterone Syst 2006; 7: 185-91.
64. Makino H, Haneda M, Babazono T, et al. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy-- rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study. J Int Med Res 2005; 33: 677-86.
65. Makino H, Haneda M, Babazono T, et al. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res 2008; 31: 657-64.
66. Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C, VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008; 23: 3174-83.
67. Toth PP. Review of the AMADEO study: reducing proteinuria in patients with diabetic nephropathy with telmisartan versus losartan. Commentary. Postgrad Med 2010; 122: 165-8.
68. Masuda S, Tamura K, Wakui H, et al. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertens Res 2009; 32: 950-5.
69. Balakumar P, Arora MK, Singh M. Emerging role of PPAR ligands in the management of diabetic nephropathy. Pharmacol Res 2009; 60: 170-3.
70. Ko GJ, Kang YS, Han SY, et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant 2008; 23: 2750-60.
71. Ohga S, Shikata K, Yozai K, et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol 2007; 292: F1141-50.
72. Arora MK, Reddy K, Balakumar P. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetesinduced experimental nephropathy. Eur J Pharmacol 2010; 636: 137-44.
73. Setti G, Hayward A, Dessapt C, et al. Peroxisome proliferatoractivated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes. Am J Nephrol 2010; 32: 393-402.
74. Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005; 54: 2206-11.
75. Kim MK, Ko SH, Baek KH, et al. Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes. Korean J Intern Med 2009; 24: 227-32.
76. Lennon R, Welsh GI, Singh A, et al. Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1. Diabetologia 2009; 52: 1944-52.
77. Balakumar P, Mahadevan N. Interplay between statins and PPARs in improving cardiovascular outcomes: A double-edged sword? Br J Pharmacol 2012; 165: 373-9.
78. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
79. Mann JF, Schmieder RE, McQueen M, et al. ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-53.
80. Mann JF, Schmieder RE, Dyal L, et al. TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009; 151: 1-10, W1-2.
81. Oparil S, Kjeldsen SE, Hedner T, Narkiewicz K. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading? Blood Press 2009; 18: 4-6.
82. Barnett AH, Bain SC, Bouter P, et al. Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-61.